New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
07:42 EDTEPZMEpizyme initiates pediatric MLL-r proof-of-concept study for leukemia candidate
Epizyme initiated a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene. This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Expected data disclosure date is in 2H14.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
10:12 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information
August 13, 2014
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
August 12, 2014
17:12 EDTEPZMEpizyme reports MTD not reached in 3 dose cohorts from EPZ-6438 Phase 1 trial
Subscribe for More Information
15:56 EDTEPZMEpizyme rises 5.3% to $35.93
A late day move higher in shares of Epizyme came in concert with the posting of a presentation dated August 12, entitled "EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations," to the company's website. Reference Link
15:23 EDTEPZMNotable companies reporting before tomorrow's open
Subscribe for More Information
August 11, 2014
06:54 EDTEPZMAmerican Society of Hematology to hold a meeting
Subscribe for More Information
August 7, 2014
15:31 EDTEPZMEpizyme management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use